{
    "nct_id": "NCT05438602",
    "official_title": "AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Current need for hospitalization or anticipated need for hospitalization within 24 h after randomization\n* Known medical history of active liver disease\n* Known HIV infection with a viral load >400 copies/mL or taking prohibited medications for human immunodeficiency virus (HIV)\n* Receiving dialysis or have known age-specific estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) <30 mL/min/1.73 m2 at screening as measured by a serum creatinine point of care device\n* Oxygen saturation of <92% on room air obtained at rest within 24 hours prior to randomization\n* Current use of any prohibited concomitant medication(s)\n* Females who are pregnant and <14 weeks gestation",
    "miscellaneous_criteria": "Inclusion Criteria (applicable for both the main population and population with rebound):\n\n* Participants aged 12 years or older and weighing ≥40 kg at screening.\n* Immunocompromised\n* ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization.\n\nParticipants for the main population must have:\n\n- Confirmed SARS-CoV-2 infection as determined by RT-PCR or other acceptable test method in any specimen collected within 5 days prior to randomization for the main study population.\n\nParticipants form the rebound population must have:\n\n- Confirmed SARS-CoV-2 infection as determined by RT-PCR or rapid antigen testing in any specimen collected within 24h prior to randomization and collected within 14 days after the completion of the initial 5-day treatment course of nirmatrelvir/ritonavir for the population with rebound."
}